R1 690,00
Mitochondrial Repair and Energy Booster, Muscle Strength, Endurance, Heart Function, Neuroprotection.
R1 690,00
4 in stock
SS-31 is a lab-made synthetic tetrapeptide – a tiny chain of just 4 amino acids (D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH) designed to penetrate cells and selectively target the inner mitochondrial membrane.
Developed by Dr. Hazel Szeto at Cornell and advanced by Stealth BioTherapeutics, it ss the world’s first approved mitochondria-targeted therapy. Unlike most peptides we’ve covered, it is not a general ‘repair’ or hormone signal, it specifically protects and restores the cell’s power plants (mitochondria) by binding cardiolipin.
Think of SS-31 as a ‘mitochondrial bodyguard.’ It goes straight to the inner mitochondrial membrane and fixes the damage that causes energy failure.
How it works (super simple):
– Selectively binds cardiolipin (a key lipid in the inner membrane).
– Stabilizes electron transport chain supercomplexes, reduces harmful reactive oxygen species (ROS), prevents membrane leakage, and restores ATP production.
SS-31 has an excellent safety profile across trials, one of the cleanest mitochondria-targeted compounds tested.
In FDA approval data and long-term extension (TAZPOWER): Well-tolerated for years.
Most common (mild-moderate):
– Injection-site reactions (redness, itching, swelling, pain, most frequent but usually improve).
– Mild fatigue or headache (rare and transient).
– No major organ toxicity or serious systemic effects in studies.
– Accelerated approval means ongoing confirmatory trials are required.
– Theoretical hypersensitivity risk (rare).
Bottom line: Far safer than many experimental peptides, side effects are almost entirely local to the injection site.
Reconstitute 2ml bac water into 50mg SS31 Vial. See Reconstitution Guide
Dosage:
Daily 2mg. Draw 2ml of Bac water and reconstitute with 10mg vial. Draw 40 units on 1ml syringe and administer subcutaneously every morning. One vial lasts 5 days.
For the 50mg – 2ml bac water into vial. Draw 8 units daily. Should last 25 days.
Cycling: Do the above for 4 weeks 3 times a year.
SS-31 now has real FDA approval data plus long-term follow-up -stronger regulatory backing than most peptides.
1. FDA approval announcement (Sept 19, 2025): Accelerated approval for Barth syndrome 30 kg based on muscle strength improvements; first mitochondria-targeted drug.
2. Thompson et al. (2024, updated 2025) TAZPOWER 168-week OLE: Sustained muscle strength, cardiac function, and exercise capacity improvements; well-tolerated with mostly injection-site reactions.
4. Tung et al. (2025) PMC review: Comprehensive mechanism (cardiolipin binding, ROS reduction, ATP restoration); potential in heart failure, neurodegeneration, and aging.
5. Karaa et al. (2023) MMPOWER-3 Phase 3: Safety confirmed but missed primary endpoints in primary mitochondrial myopathy (well-tolerated overall).
8. Swolverine / clinical summaries (2025-2026): Mitochondrial protection, dosing (140 mg), and exceptional safety profile.
9. Johns Hopkins / IRCM updates (2025-2026): Co-discovery and real-world Barth syndrome improvements in strength and quality of life.
10. Paragon Sports Medicine / research overviews (2026): Exceptional safety; minimal systemic toxicity; 1-40 mg daily range.
Chromatin activation, Gene Expression, Immune System Support, Liver and GI tract Optimization, Anti-aging & Cellular Rejuvenation.
R550,00
Fat-Loss, Fat Oxidation, Androgen Receptor, Metabolism Booster, Lung, Kidney and Heart Health Booster.
R560,00
Energy, Focus, Mood Boost, Mental Clarity, Reduced Fatigue, Addiction Recovery, Anti- Aging, Neuroprotection, Reduced Inflammation.
R1 650,00
Muscle Growth, Fat Loss, Recovery, Better Sleep, Mood, Anti-Aging, Better Skin Elasticity, Stronger Bones, Improved Energy.
R910,00
Neuroprotection, Oxidative Stress, Toxicity, Inflammation, Metabolic Health, Insulin Sensitivity, Cardiovascular Health.
R910,00
Enhanced Deep Sleep, Cognitive Benefits, Mood Enhancement, Longevity
R590,00